PLK1/BRD4-IN-5
CAT:
804-HY-158031-02
Size:
10 mM / 1 mL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
PLK1/BRD4-IN-5
- UNSPSC Description: PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research[1].
- Target Antigen: Apoptosis; Epigenetic Reader Domain; Polo-like Kinase (PLK)
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/plk1-brd4-in-5.html
- Solubility: DMSO : 100 mg/mL (ultrasonic)
- Smiles: CC[C@@H]1C(N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C5C(CCN5C(CN6C[C@@H](N[C@@H](C6)C)C)=O)=C4)OC)C)=O
- Molecular Weight: 576.73
- References & Citations: [1]Liu J, et al. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem. 2024;101:117
- Shipping Conditions: Room Temperature
- Clinical Information: No Development Reported